Table 2.

 Selected influenza antiviral agents in advanced clinical development

Agent	Viral target	Sponsor	Route	Development phase
Zanamivir	NA	GSK	IV	Phase 3
Peramivir	NA	Biocryst, Shionogi	IV	Phase 3*†
Oseltamivir	NA	Roche	IV	Phase 3
Laninamivir (CS‐8958)	NA	Biota, Daiichi‐Sankyo	Inhaled	Phase 3*
Favipiravir (T‐705)	Polymerase	Toyama	Oral	Phase 2‐3
DAS181	HA receptor	Nexbio	Inhaled	Phase 1‐2
Nitazoxanide	Possibly HA; IFN inducer	Romark	Oral	Phase 2

*Licensed in Japan.

^†licensed in South Korea.